AHP ACQUISITION OF CYANAMID WOULD ADD ORTHOPEDICS, OPHTHALMIC
This article was originally published in The Gray Sheet
Executive SummaryAHP ACQUISITION OF CYANAMID WOULD ADD ORTHOPEDICS, OPHTHALMIC devices to American Home Products' portfolio. AHP's $8.53 bil. bid for Cyanamid would give the company the Acufex orthopedic device and the Storz ophthalmic subsidiaries, both of which would represent new territory for AHP.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.